Image Guided and Adaptive Radiotherapy in Clinical Practice: Including SABR Topics
Course Dates: 12th - 13th February 2026
Course overview
This course is designed to help clinicians, physicists and radiographers to develop comprehensive programmes for the clinical implementation of image guided radiotherapy. The course has been awarded 19 RCR Category I CPD credits under The Royal College of Radiologists CPD scheme.
The curriculum covers many practical aspects and includes hands-on practical sessions, image matching, QA and dosimetry. It is recommended that a team of oncologist, physicist and radiographer from the same centre attend together.
The course is for two days and included in the cost are a set of lecture notes, a digital copy of the actual presentations, lunches, refreshments in the day, and evening pizza and cheese and wine event.
Day one: Lectures on patient preparation and immobilisation, surface guided RT, New technology; Radixact, HyperSight, Elekta solutions, Imaging and margins in head and neck cancers, margins for geometric uncertainty, adaptive pathways.
Practical hands-on sessions on the use of Image Guidance protocols, QA, Dosimetry, and a journey through the patient pathway. These sessions will be scheduled in the evening on Day one.
Day two: Lectures on advanced techniques for gynaecological cancer, AI in clinical pathway, Renal Cancer SBRT, SBRT for lung including 4D motion management, Verification for lung tumours, current prostate trials, adaptive radiotherapy for bladder cancer.
Downloads
Download the IGART Draft programme 2026 detailed course information.
Payment options
Invoice payment please contact: Cheryl Taylor for details
BACS/ overseas transfers please contact: Cheryl Taylor for details
Course organisers
- Ms Margaret Bidmead
- Dr Helen McNair
- Ms Sophie Alexander
Contacts
Margaret Bidmead (Course Creator)
Tel: 020 7808 2506
Fax: 020 7808 2522
This course has been accredited under The Royal College of Radiologists CPD scheme.
Related pages
Latest ICR News
Breakthrough discovery reveals new drug target to stop pancreatic cancer spreading
Scientists have discovered a key protein that could be targeted with a drug to treat the most common and aggressive form of pancreatic cancer.
ICR and Enamine announce new collaboration in fragment-based drug discovery
The Institute of Cancer Research and Enamine Ltd. have announced a new research collaboration aimed at broadening the tools available for researchers working in fragment-based drug discovery (FBDD).